PLA2G6 and neurodevelopmental disorder: In case 10, in addition to the compound heterozygous PLA2G6 variants already reported after ultrarapid LR-GS, standard genomic care identified a heterozygous pathogenic variant in IRF2BPL (Neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures; MIM#618088).